In vivo experiments demonstrated that combining exo/si-LINC02544 with PD-L1 inhibitors significantly inhibited tumor growth, increased CD8 + T cell infiltration, and reduced the proportion of Treg cells (Fig. 10), suggesting potential in reversing immune therapy resistance. This evidence concerns the gene CD8A and neoplasm.